Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 19/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142791 | 0.85 | ICAM1 (0.49) | ICAM1KDM4EGAAMAPTHPGD | |
| SCHEMBL6747419 | 0.84 | ICAM1 (0.53) | ICAM1KDM4EGAAMAPTHPGD | |
| SCHEMBL6750217 | 0.83 | NOX1 (0.56) | ICAM1KDM4EGAAMAPTHPGD | |
| SCHEMBL6747182 | 0.82 | KDM4E (0.57) | ICAM1KDM4EGAAMAPTHPGD | |
| SCHEMBL6749358 | 0.81 | KDM4E (0.51) | ICAM1KDM4EGAAMAPTHPGD | |
| Hydrochloric Acid SCHEMBL6745390 | 0.79 | ICAM1 (0.49) | ICAM1KDM4EGAAMAPTHPGD | |
| SCHEMBL6746538 | 0.79 | ICAM1 (0.59) | ICAM1KDM4EGAAMAPTHPGD | |
| SCHEMBL6749135 | 0.78 | ICAM1 (0.50) | ICAM1KDM4EGAAMAPTHPGD | |
| SCHEMBL6745764 | 0.77 | KDM4E (0.54) | ICAM1KDM4EGAAMAPTHPGD | |
| SCHEMBL6749642 | 0.77 | ICAM1 (0.48) | ICAM1KDM4EGAAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | ICAM1 412/4885KDM4E 1573/4885GAA 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.